Summary:
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GT20029 Following Topical Single Ascending Dose Administration in Healthy Subjects and Multiple Ascending Dose Administration in subjects with Androgenetic Alopecia (AGA) or Acne
Qualified Participants Must:
• Have an Acne breakout
• Must be 18 to 60 years old
• Have a BMI between 18 and 30
• Must be avaliable for a 17 day/16 Night Stay at the Research Center with 1 follow up visit.
Qualified Participants May Receive:
Compensation up to $8150.00